USFDA inspection at Pithampur facility yields 7 observations

Regulatory & Legal View source PDF Explain this filing

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹1422.00

prior close

₹1413.50

announcement price

After-mkt

timing

Nifty 100market-0.4%-0.4% vs market

Pharmaceuticals peers, median of 175sector+0.3%-1.1% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty 100 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

+0.4

15m

+0.1

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-0.4-0.4+0.3-1.1

Next day

-0.6-0.9+0.3+0.4-1.0

-0.5-0.6+0.1+0.7-1.2

-0.9-1.0+0.1+1.0-1.9

-0.4-1.3+1.0+0.5-0.9

-0.9-1.8+0.9+0.7-1.6

-2.6-1.9-0.7+1.2-3.8

15d

-2.6-4.4+1.8+1.0-3.6

-2.7-6.2+3.6-0.5-2.2

-5.3-7.3+2.0-6.0+0.8

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 175Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA completed a follow-up cGMP inspection at Cipla's Pithampur manufacturing facility from 17 to 25 August 2026. The inspection concluded with 7 inspectional observations in Form 483. Cipla stated it will work closely with the regulator and address these comprehensively within the stipulated timeline.

Likely market impact

Seven observations may pressure near-term sentiment. Risk of escalation to a warning letter if unresolved, potentially affecting US exports.